Does mild persistent asthma require regular treatment?

New England Journal of Medicine

Volumn 352, Issue 15, 2005, Pages 1589-1591

  Fabbri, Leonardo M ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; ZAFIRLUKAST; ANTIASTHMATIC AGENT; TOLUENESULFONIC ACID DERIVATIVE;

CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EDITORIAL; HUMAN; LUNG FUNCTION; MILD PERSISTENT ASTHMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; ASTHMA; CLASSIFICATION; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; NOTE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; DRUG ADMINISTRATION SCHEDULE; HUMANS; TOSYL COMPOUNDS;

EID: 16844373533     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058020     Document Type: Editorial

References (15)

1. NAEPP Expert Panel report: guidelines for the diagnosis and management of asthma - update on selected topics 2002. Bethesda, Md.: National Heart, Lung, and Blood Institute, June 2002. (NIH publication no. 02-5075.)
2. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO workshop report. Updated 2004. Bethesda, Md.: National Heart, Lung, and Blood Institute, 2004.
3. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071-6.
4. O'Byrne PM, Barnes PJ, Rodriguez-Rpisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164: 1392-7.
5. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054-63.
6. Vignola AM. Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting beta2-agonists on asthma pathophysiology: a review of the evidence. Drugs 2003;63:Suppl 2:35-51.
7. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28.
8. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma. Chest 2000;117:440-6.
9. FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004;59:550-6.
10. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363:271-5.
11. Louis R, Sele J, Henket M, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 2002;57:907-12.
12. Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 2003;21:433-8.
13. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000;355: 1399-403.
14. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005;171:109-14.
15. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.